Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target

被引:1
|
作者
Dattani, Abhishek [1 ]
Singh, Anvesha
Mccann, Gerry P.
Gulsin, Gaurav S.
机构
[1] Univ Leicester, Dept Cardiovasc Sci, Leicester LE3 9QP, England
关键词
diabetes; calcium handling; manganese-enhanced MRI; GLYCATION END-PRODUCTS; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONGESTIVE-HEART-FAILURE; DIASTOLIC DYSFUNCTION; VENTRICULAR MYOCYTES; CARDIAC STRUCTURE; GENE-EXPRESSION; MANGANESE IONS; YOUNG-ADULTS; CARDIOMYOPATHY;
D O I
10.3390/jcdd11010012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes (T2D) is a multisystem disease with rapidly increasing global prevalence. Heart failure has emerged as a major complication of T2D. Dysregulated myocardial calcium handling is evident in the failing heart and this may be a key driver of cardiomyopathy in T2D, but until recently this has only been demonstrated in animal models. In this review, we describe the physiological concepts behind calcium handling within the cardiomyocyte and the application of novel imaging techniques for the quantification of myocardial calcium uptake. We take an in-depth look at the evidence for the impairment of calcium handling in T2D using pre-clinical models as well as in vivo studies, following which we discuss potential novel therapeutic approaches targeting dysregulated myocardial calcium handling in T2D.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes
    Chen, Rong-Bin
    Wang, Qi-Yu
    Wang, Yuan-Yuan
    Wang, Ya-Di
    Liu, Jiang-Hua
    Liao, Zhe-Zhen
    Xiao, Xin-Hua
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [22] Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function
    Jorgensen, Peter G.
    Jensen, Magnus T.
    Mogelvang, Rasmus
    Fritz-Hansen, Thomas
    Galatius, Soren
    Biering-Sorensen, Tor
    Storgaard, Heidi
    Vilsboll, Tina
    Rossing, Peter
    Jensen, Jan S.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 221 : 114 - 121
  • [23] SGLT2 inhibitors : kidney as a new therapeutic target for type 2 diabetes
    Bons, Justine
    Prevost, Gaetan
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (07): : 191 - 195
  • [24] Elevated asleep BP as predictor of type 2 diabetes and therapeutic target for prevention
    Hermida, Ramon C.
    Ayala, Diana E.
    Mojon, Artemio
    Fernandez, Jose R.
    DIABETOLOGIA, 2016, 59 (02) : 392 - 394
  • [25] SIRT1: a promising therapeutic target in type 2 diabetes mellitus
    Mihanfar, Ainaz
    Akbarzadeh, Maryam
    Darband, Saber Ghazizadeh
    Sadighparvar, Shirin
    Majidinia, Maryam
    ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 2024, 130 (01) : 13 - 28
  • [26] Oscillating blood pressure therapeutic target in type 2 diabetes patients with hypertension
    Tankeu, Aurel T.
    Noubiap, Jean Jacques N.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (21)
  • [27] Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease
    Campbell, Duncan J.
    Somaratne, Jithendra B.
    Jenkins, Alicia J.
    Prior, David L.
    Yii, Michael
    Kenny, James F.
    Newcomb, Andrew E.
    Schalkwijk, Casper G.
    Black, Mary J.
    Kelly, Darren J.
    CARDIOVASCULAR DIABETOLOGY, 2011, 10
  • [28] WWOX: A New Therapeutic Target In Type 2 Diabetes-Associated Neurodegeneration
    Carvalho, Cristina
    Moreira, Paula I.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 60 - 60
  • [29] Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes
    Henry, RR
    CLINICAL THERAPEUTICS, 2003, 25 : B47 - B63
  • [30] Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity
    Sasaoka, Toshiyasu
    Wada, Tsutomu
    Tsuneki, Hiroshi
    PHARMACOLOGY & THERAPEUTICS, 2006, 112 (03) : 799 - 809